Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
PWHL New York changing coaches with mutual agreement with Draper to step down and return to AlbertaStuart Fairchild hits insideWisconsin man gets 15 year prison sentence for 2022 building fire that killed 2 peopleChina's foreign trade growth accelerates amid improving demandMinnesota unfurls new state flag atop the capitol for the first time SaturdaySherpa guide Kami Rita scales Mount Everest for 29th time, extending his own record againSkenes strikes out 7 in debut, Pirates hit 5 homers in 10Els, Barron tied for Regions Tradition lead at 13New Mexico governor seeks hydrogen investment with trip to NetherlandsA top Cambodian opposition politician is charged with inciting disorder for criticizing government
2.4741s , 6498.9140625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Circuit news portal